Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + erythropoietin
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intravesical
01
Overview
A combination therapy consisting of epirubicin, an anthracycline chemotherapy agent, and erythropoietin, a glycoprotein hormone that stimulates red blood cell production. Epirubicin works by intercalating between DNA base pairs, inhibiting topoisomerase II activity, and interfering with DNA replication and transcription, which damages cancer cells and prevents them from dividing or growing. Erythropoietin is administered alongside epirubicin-containing chemotherapy regimens to prevent or treat chemotherapy-induced anemia by stimulating the production of red blood cells in the bone marrow.
02
Targets
DNAErythropoietin ReceptorTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on epirubicin + erythropoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + erythropoietin.